Lisata Therapeutics Inc (LSTA) Stock Price, Quote & News

Company Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimen...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 842 0100

Website: www.lisata.com

Address:

110 Allen Road, 2nd Floor, Basking Ridge, United States

PyraWeb Oct. 22 at 5:25 PM

$LSTA A good listen. I continue to be hyped on the science…but obviously data isnt/hasn’t done much for the company, so I hope Mazzo gets off that and into the $$$ deals. It’s a super thinly traded stock, I hope they release something the market can’t ignore.

0 · Reply

TwongStocks Oct. 21 at 3:31 PM

$LSTA LD Micro presentation was yesterday. Had a chance to listen to the on-demand replay https://ldmicrocasts.com/ Big takeaway at around the 2:11:15 mark of the video. Seems they are looking to partner out the phase 3 PDAC trial: • Poised for initiation of phase 3 in PDAC • Looking at a combination of raising some capital to contribute to it, but mostly plan to complete development with partners • Looking for potential partners who want to pair certepetide with their checkpoint inhibitor or chemotherapeutic biosimilars • Expect a licensing agreement to complete the phase 3 in pancreatic cancer

2 · Reply

natyar Oct. 15 at 3:45 PM

$LSTA $PULM undervalued

0 · Reply

TwongStocks Oct. 14 at 8:18 PM

$LSTA New investor presentation https://ir.lisata.com/static-files/25b9b5e8-eb55-473e-a4cc-b89fa2d4108f • Per slide 7 & slide 50, cash runway is now into Q1 2027 (improved). In the Aug ER, they reported cash runway into Q4 2026. • Slide 48 has upcoming clinical milestones.

0 · Reply

lookingaroundhere Oct. 13 at 6:29 PM

$LSTA data that supports moving into phase 3 - worth a look.

0 · Reply

builderup Oct. 13 at 5:59 PM

Let’s go! Add these to your lists. It’s almost GO time. $LSTA $MCHX $IVA

0 · Reply

newsfile_corp Oct. 13 at 12:01 PM

https://nfne.ws/269816 $LSTA #ldmicro #Publishing #NASDAQ #Investing

0 · Reply

TwongStocks Oct. 12 at 10:15 PM

$LSTA ESMO Congress abstract is now available https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal_2/presentation/list?q=Ascend&r=pt%7E13 Cohort A vs pooled placebo 6m PFS 49.0% vs 34.1% mPFS 5.6 months 5.3m mOS 12.68m vs 9.23m ORR 35.4% vs 24.5% Cohort B vs pooled placebo 6m PFS 60.8% vs 34.1% mPFS 7.46m vs 5.3m mOS 10.32m vs 9.23m ORR 45.2% vs 24.5%

1 · Reply

Pastures Oct. 11 at 7:09 AM

$LSTA Once the results come out how much are people hoping for per share?

1 · Reply

TwongStocks Oct. 9 at 8:32 PM

$LSTA The pooled Cohort A and Cohort B data from ASCEND will be presented at this month's ESMO Congress in Berlin. Abstract embargo will be lifted at 00:05 CEST (central European summer time) on Oct 13, 6:05pm EDT Oct 12.

1 · Reply

Lisata Therapeutics to Present at LD Micro Main Event XIX

Oct 8, 2025, 8:30 AM EDT - 17 days ago

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

Sep 29, 2025, 8:00 AM EDT - 26 days ago

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

Sep 2, 2025, 8:00 AM EDT - 7 weeks ago

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 8, 2025, 3:05 AM EDT - 2 months ago

Lisata Therapeutics, Inc. (LSTA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 AM EDT - 3 months ago

Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 3 months ago

Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update

Jul 15, 2025, 8:00 AM EDT - 3 months ago

Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide

Jun 17, 2025, 8:00 AM EDT - 4 months ago

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

Jun 11, 2025, 8:30 AM EDT - 4 months ago

Lisata Therapeutics to Present at the 2025 BIO International Convention

May 8, 2025, 9:57 PM EDT - 6 months ago

Lisata Therapeutics, Inc. (LSTA) Q1 2025 Earnings Conference Call Transcript

May 8, 2025, 4:05 PM EDT - 6 months ago

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:00 AM EDT - 6 months ago

Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025

Apr 15, 2025, 8:00 AM EDT - 6 months ago

Lisata Therapeutics Announces Research License with Catalent

Mar 6, 2025, 8:30 AM EST - 8 months ago

Lisata Therapeutics to Present at the Investival Showcase USA

Mar 5, 2025, 8:30 AM EST - 8 months ago

Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

Feb 27, 2025, 10:06 PM EST - 8 months ago

Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 8 months ago

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Feb 20, 2025, 8:00 AM EST - 8 months ago

Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025

Jan 15, 2025, 8:30 AM EST - 10 months ago

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

Dec 10, 2024, 8:30 AM EST - 11 months ago

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

Nov 19, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year'

Nov 12, 2024, 10:07 PM EST - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 1 year ago

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 9:23 AM EST - 1 year ago

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

Nov 6, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

Aug 13, 2024, 12:20 AM EDT - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

Jul 16, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

Jun 13, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

May 28, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

May 20, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

May 9, 2024, 9:42 PM EDT - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 1 year ago

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

Apr 23, 2024, 7:30 AM EDT - 1 year ago

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Apr 9, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Apr 3, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

Mar 21, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Feb 29, 2024, 8:41 PM EST - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:05 PM EST - 1 year ago

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Feb 22, 2024, 8:00 AM EST - 1 year ago

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

Feb 20, 2024, 8:00 AM EST - 1 year ago

Lisata Therapeutics to Present at BIO CEO & Investor Conference

Jan 18, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico

PyraWeb Oct. 22 at 5:25 PM

0 · Reply

TwongStocks Oct. 21 at 3:31 PM

2 · Reply

natyar Oct. 15 at 3:45 PM

$LSTA $PULM undervalued

0 · Reply

TwongStocks Oct. 14 at 8:18 PM

0 · Reply

lookingaroundhere Oct. 13 at 6:29 PM

$LSTA data that supports moving into phase 3 - worth a look.

0 · Reply

builderup Oct. 13 at 5:59 PM

Let’s go! Add these to your lists. It’s almost GO time. $LSTA $MCHX $IVA

0 · Reply

newsfile_corp Oct. 13 at 12:01 PM

https://nfne.ws/269816 $LSTA #ldmicro #Publishing #NASDAQ #Investing

0 · Reply

TwongStocks Oct. 12 at 10:15 PM

1 · Reply

Pastures Oct. 11 at 7:09 AM

$LSTA Once the results come out how much are people hoping for per share?

1 · Reply

TwongStocks Oct. 9 at 8:32 PM

1 · Reply

emile_ Oct. 9 at 5:20 PM

$LSTA buy or sell before full ascend trial data?

0 · Reply

EdwardTeach Oct. 9 at 5:11 PM

$LSTA someone is holding this down...glta

0 · Reply

Slide3 Oct. 9 at 2:31 PM

$LSTA Is the purpose of binding certepetide to an antibody, to get more certepetide into the tumor, or to open the membrane so other drugs and ADCs can enter the tumor, or both?

1 · Reply

TwongStocks Oct. 9 at 1:25 PM

$LSTA Fierce Biotech article on yesterday's news https://www.fiercebiotech.com/biotech/cdmo-catalent-strengthens-adc-pipeline-10m-pact-lisata-tumor-drug

0 · Reply

Slide3 Oct. 8 at 3:53 PM

$LSTA I think whatever big boys who support this stock were not informed beforehand and are holding it down to accumulate more. That's my story and I'm staying with it . Catalent was supposed to report their decision in June and took 4 months extra, either it was technically difficult or they were very interested in what they found. If this news doesn't really the stock eventually, someone will buy it. JMO DYODD

0 · Reply

emile_ Oct. 8 at 3:25 PM

$LSTA market thinks that the Catalent license deal will not go far from preclinical?

1 · Reply

EdwardTeach Oct. 8 at 3:08 PM

$LSTA this is the loading zone....glta

0 · Reply

m1ster_leboeuf Oct. 8 at 2:13 PM

$LSTA

0 · Reply

Slide3 Oct. 8 at 1:46 PM

$LSTA Amazing, the market is asleep on this. Merck invested $6 billion in ADCs , they're not going to want to enhance their penetration?

0 · Reply

drwaz Oct. 8 at 1:24 PM

$LSTA This will run

0 · Reply

EdwardTeach Oct. 8 at 1:13 PM

$LSTA "Under the terms of the agreement, Lisata is eligible to receive over $10 million in tiered study initiation milestone payments plus revenue sharing on future sales and partnerships." "Catalent gains global rights to evaluate certepetide for ADC payloads" https://in.investing.com/news/company-news/catalent-gains-global-rights-to-evaluate-certepetide-for-adc-payloads-93CH-5035340

0 · Reply

PyraWeb Oct. 8 at 1:08 PM

$LSTA awesome news! A deal with Catalent! This is what we are looking for! Now let’s see how the stupid market reacts. Hopefully this finally gets a ton of volume.

1 · Reply

Market Cap	20.58M
Revenue (ttm)	1.00M
Net Income (ttm)	-19.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,999.00%
Debt to Equity Ratio	0.00

Volume	9,000
Avg Vol	30,372
Day's Range	N/A - N/A
Shares Out	8.76M
Stochastic %K	26%
Beta	1.04
Analysts	Strong Sell
Price Target	$23.50